Chlortetracycline, a Novel Arf Inhibitor that Decreases the Arf6-Dependent Invasive Properties of Breast Cancer Cells
Breast cancer is a major disease for women worldwide, where mortality is associated with tumour cell dissemination to distant organs. While the number of efficient anticancer therapies increased in the past 20 years, treatments targeting the invasive properties of metastatic tumour cells are still a...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/26/4/969 |
id |
doaj-e4d3d005e5dc453380a0885aa347ff2e |
---|---|
record_format |
Article |
spelling |
doaj-e4d3d005e5dc453380a0885aa347ff2e2021-02-13T00:00:59ZengMDPI AGMolecules1420-30492021-02-012696996910.3390/molecules26040969Chlortetracycline, a Novel Arf Inhibitor that Decreases the Arf6-Dependent Invasive Properties of Breast Cancer CellsEric Macia0Monserrat Vazquez-Rojas1Alessia Robiolo2Racha Fayad3Sophie Abélanet4Isabelle Mus-Veteau5Fabien Fontaine-Vive6Mohamed Mehiri7Frédéric Luton8Michel Franco9Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), UMR 7275 CNRS-Université Côte d’Azur, 660, route des lucioles, 06560 Valbonne, FranceInstitut de Pharmacologie Moléculaire et Cellulaire (IPMC), UMR 7275 CNRS-Université Côte d’Azur, 660, route des lucioles, 06560 Valbonne, FranceInstitut de Pharmacologie Moléculaire et Cellulaire (IPMC), UMR 7275 CNRS-Université Côte d’Azur, 660, route des lucioles, 06560 Valbonne, FranceInstitut de Pharmacologie Moléculaire et Cellulaire (IPMC), UMR 7275 CNRS-Université Côte d’Azur, 660, route des lucioles, 06560 Valbonne, FranceInstitut de Pharmacologie Moléculaire et Cellulaire (IPMC), UMR 7275 CNRS-Université Côte d’Azur, 660, route des lucioles, 06560 Valbonne, FranceInstitut de Pharmacologie Moléculaire et Cellulaire (IPMC), UMR 7275 CNRS-Université Côte d’Azur, 660, route des lucioles, 06560 Valbonne, FranceInstitut de Chimie de Nice (ICN), UMR 7272 CNRS-Université Côte d’Azur, 28, avenue de Valrose, CEDEX 2, 06108 Nice, FranceInstitut de Chimie de Nice (ICN), UMR 7272 CNRS-Université Côte d’Azur, 28, avenue de Valrose, CEDEX 2, 06108 Nice, FranceInstitut de Pharmacologie Moléculaire et Cellulaire (IPMC), UMR 7275 CNRS-Université Côte d’Azur, 660, route des lucioles, 06560 Valbonne, FranceInstitut de Pharmacologie Moléculaire et Cellulaire (IPMC), UMR 7275 CNRS-Université Côte d’Azur, 660, route des lucioles, 06560 Valbonne, FranceBreast cancer is a major disease for women worldwide, where mortality is associated with tumour cell dissemination to distant organs. While the number of efficient anticancer therapies increased in the past 20 years, treatments targeting the invasive properties of metastatic tumour cells are still awaited. Various studies analysing invasive breast cancer cell lines have demonstrated that Arf6 is an important player of the migratory and invasive processes. These observations make Arf6 and its regulators potential therapeutic targets. As of today, no drug effective against Arf6 has been identified, with one explanation being that the activation of Arf6 is dependent on the presence of lipid membranes that are rarely included in drug screening. To overcome this issue we have set up a fluorescence-based high throughput screening that follows overtime the activation of Arf6 at the surface of lipid membranes. Using this unique screening assay, we isolated several compounds that affect Arf6 activation, among which the antibiotic chlortetracycline (CTC) appeared to be the most promising. In this report, we describe CTC in vitro biochemical characterization and show that it blocks both the Arf6-stimulated collective migration and cell invasion in a 3D collagen I gel of the invasive breast cancer cell line MDA-MB-231. Thus, CTC appears as a promising hit to target deadly metastatic dissemination and a powerful tool to unravel the molecular mechanisms of Arf6-mediated invasive processes.https://www.mdpi.com/1420-3049/26/4/969small G proteininhibitorcell invasionArf6breast cancerchlortetracycline |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Eric Macia Monserrat Vazquez-Rojas Alessia Robiolo Racha Fayad Sophie Abélanet Isabelle Mus-Veteau Fabien Fontaine-Vive Mohamed Mehiri Frédéric Luton Michel Franco |
spellingShingle |
Eric Macia Monserrat Vazquez-Rojas Alessia Robiolo Racha Fayad Sophie Abélanet Isabelle Mus-Veteau Fabien Fontaine-Vive Mohamed Mehiri Frédéric Luton Michel Franco Chlortetracycline, a Novel Arf Inhibitor that Decreases the Arf6-Dependent Invasive Properties of Breast Cancer Cells Molecules small G protein inhibitor cell invasion Arf6 breast cancer chlortetracycline |
author_facet |
Eric Macia Monserrat Vazquez-Rojas Alessia Robiolo Racha Fayad Sophie Abélanet Isabelle Mus-Veteau Fabien Fontaine-Vive Mohamed Mehiri Frédéric Luton Michel Franco |
author_sort |
Eric Macia |
title |
Chlortetracycline, a Novel Arf Inhibitor that Decreases the Arf6-Dependent Invasive Properties of Breast Cancer Cells |
title_short |
Chlortetracycline, a Novel Arf Inhibitor that Decreases the Arf6-Dependent Invasive Properties of Breast Cancer Cells |
title_full |
Chlortetracycline, a Novel Arf Inhibitor that Decreases the Arf6-Dependent Invasive Properties of Breast Cancer Cells |
title_fullStr |
Chlortetracycline, a Novel Arf Inhibitor that Decreases the Arf6-Dependent Invasive Properties of Breast Cancer Cells |
title_full_unstemmed |
Chlortetracycline, a Novel Arf Inhibitor that Decreases the Arf6-Dependent Invasive Properties of Breast Cancer Cells |
title_sort |
chlortetracycline, a novel arf inhibitor that decreases the arf6-dependent invasive properties of breast cancer cells |
publisher |
MDPI AG |
series |
Molecules |
issn |
1420-3049 |
publishDate |
2021-02-01 |
description |
Breast cancer is a major disease for women worldwide, where mortality is associated with tumour cell dissemination to distant organs. While the number of efficient anticancer therapies increased in the past 20 years, treatments targeting the invasive properties of metastatic tumour cells are still awaited. Various studies analysing invasive breast cancer cell lines have demonstrated that Arf6 is an important player of the migratory and invasive processes. These observations make Arf6 and its regulators potential therapeutic targets. As of today, no drug effective against Arf6 has been identified, with one explanation being that the activation of Arf6 is dependent on the presence of lipid membranes that are rarely included in drug screening. To overcome this issue we have set up a fluorescence-based high throughput screening that follows overtime the activation of Arf6 at the surface of lipid membranes. Using this unique screening assay, we isolated several compounds that affect Arf6 activation, among which the antibiotic chlortetracycline (CTC) appeared to be the most promising. In this report, we describe CTC in vitro biochemical characterization and show that it blocks both the Arf6-stimulated collective migration and cell invasion in a 3D collagen I gel of the invasive breast cancer cell line MDA-MB-231. Thus, CTC appears as a promising hit to target deadly metastatic dissemination and a powerful tool to unravel the molecular mechanisms of Arf6-mediated invasive processes. |
topic |
small G protein inhibitor cell invasion Arf6 breast cancer chlortetracycline |
url |
https://www.mdpi.com/1420-3049/26/4/969 |
work_keys_str_mv |
AT ericmacia chlortetracyclineanovelarfinhibitorthatdecreasesthearf6dependentinvasivepropertiesofbreastcancercells AT monserratvazquezrojas chlortetracyclineanovelarfinhibitorthatdecreasesthearf6dependentinvasivepropertiesofbreastcancercells AT alessiarobiolo chlortetracyclineanovelarfinhibitorthatdecreasesthearf6dependentinvasivepropertiesofbreastcancercells AT rachafayad chlortetracyclineanovelarfinhibitorthatdecreasesthearf6dependentinvasivepropertiesofbreastcancercells AT sophieabelanet chlortetracyclineanovelarfinhibitorthatdecreasesthearf6dependentinvasivepropertiesofbreastcancercells AT isabellemusveteau chlortetracyclineanovelarfinhibitorthatdecreasesthearf6dependentinvasivepropertiesofbreastcancercells AT fabienfontainevive chlortetracyclineanovelarfinhibitorthatdecreasesthearf6dependentinvasivepropertiesofbreastcancercells AT mohamedmehiri chlortetracyclineanovelarfinhibitorthatdecreasesthearf6dependentinvasivepropertiesofbreastcancercells AT fredericluton chlortetracyclineanovelarfinhibitorthatdecreasesthearf6dependentinvasivepropertiesofbreastcancercells AT michelfranco chlortetracyclineanovelarfinhibitorthatdecreasesthearf6dependentinvasivepropertiesofbreastcancercells |
_version_ |
1724272652546211840 |